Nanoparticles deliver 'suicide gene' therapy to pediatric brain tumors growing in mice

January 08, 2020

Johns Hopkins researchers report that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a "suicide gene" to pediatric brain tumor cells implanted in the brains of mice. The poly(beta-amino ester) nanoparticles, known as PBAEs, were part of a treatment that also used a drug to kill the cells and prolong the test animals' survival.

In their study, described in a report published January 2020 in the journal Nanomedicine: Nanotechnology, Biology and Medicine, the researchers caution that for safety and biological reasons, it is unlikely that the suicide gene herpes simplex virus type I thymidine kinase (HSVtk) -- which makes tumor cells more sensitive to the lethal effects of the anti-viral drug ganciclovir -- could be the exact therapy used to treat human medulloblastoma and atypical teratoid/rhabdoid tumors (AT/RT) in children.

So-called "suicide genes" have been studied and used in cancer treatments for more than 25 years. The HSVtk gene makes an enzyme that helps restore the function of natural tumor suppression.

Specifically, the experiments found that a combination of the suicide gene and ganciclovir delivered by intraperitoneal injection to mice killed more than 65% of the two types of pediatric brain tumor cells. The combination was deliberately "transfected" with the gene seven days after the nanoparticle therapy was used to deliver the genetic material. Mice bearing an AT/RT-type tumor lived 20% longer after receiving the treatment -- 42 days, compared to 35 days for untreated mice. Those with a group 3 medulloblastoma-type tumor implanted in the brain lived 63% longer, surviving 31 days compared to 19 days for untreated mice.

"It's an exciting alternate way to be able to deliver gene therapy to a tumor in a selective fashion that targets only tumor cells," says Eric Jackson, M.D., associate professor of neurosurgery at the Johns Hopkins University School of Medicine. "Our idea now is to find other collaborators who may have a gene therapy that they think would work well to kill these tumors."

Medulloblastoma and AT/RT are two of the most prevalent and deadly pediatric brain malignancies. Traditional treatments, including radiation, can harm healthy tissue as well as the tumor, and can produce long-lasting developmental side effects in growing children, making it critical to find new therapies, Jackson notes.

Gene therapy that targets only cancer cells is a promising treatment avenue, but many gene therapy methods use a modified virus to deliver their therapeutic payloads of DNA, a method that may not be safe or suitable for pediatric use. "A lot of these viruses are safe if you have a mature immune system, but in very young patients with more fragile immune systems, a virus delivery system may pose additional risks," says Jackson.

To address this issue, Jackson collaborated with Jordan Green, Ph.D., an investigator at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy, director of the Johns Hopkins Biomaterials and Drug Delivery Laboratory and professor of biomedical engineering, to find a different kind of carrier for gene therapy. Green and his colleagues developed the PBAE class of polymeric nanoparticles, which can be engineered to bind and carry DNA.

The biodegradable PBAEs are injected into a tumor mass where they safely release their DNA cargo after being ingested by tumor cells. In previous studies that used similar particles to deliver gene therapy to adult brain cancers and liver cancers in cell cultures and in rodents, Green and his colleagues found that the nanoparticles preferentially target tumor cells over healthy cells.

The mechanism that allows the particles to target tumor cells preferentially is still being investigated, but Green thinks "the chemical surface of the particle is likely interacting with proteins that are on the surface of certain types of cancer cells."

Green and his colleagues altered the nanoparticles to target the two pediatric malignancies. "By making small chemical changes to the polymers that make up the nanoparticles, we can significantly change the cellular uptake into particular kinds of cancer cells, and the subsequent gene delivery to the cytosol, in a cell-specific way," Green says.

Jackson says he hopes the nanoparticles can be used to deliver a variety of gene-based treatments - including therapies that alter the expression levels of genes, turn genes on and off altogether, or sensitize cells to other therapies - depending on the specifics of a patient's tumor. "In some ways, we're still in the discovery phase of what genes to target" in medulloblastoma and AT/RT, he says.

The nanoparticles "can carry larger genes than what can be carried by a virus, and can carry combinations of genes," says Green. "It's a platform that doesn't have limitations on the cargo size being delivered, or limitations related to immunogenicity or toxicity. And, it is easier to manufacture than a virus."
-end-
Other Johns Hopkins researchers involved in the study were John Choi, Yuan Rui, Jayoung Kim, Noah Gorelick, David Wilson, Kristen Kozielski, Antonella Mangraviti, Eric Sankey, Henry Brem and Betty Tyler.

The research was supported by the National Institutes of Health (R01CA228133).

The scientists are filing for patents related to this work.

Johns Hopkins Medicine

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.